However, the application of this approach in routine practice may be facilitated by the fact that HER2/Chr17 in situ hybridization is the same technique that is widely used in the everyday pathological workflow of breast cancer diagnostics; it can therefore be easily and quickly adapted to bladder cancer diagnostics. Here, ERBB2 is linked to urinary bladder cancer.